SCHEMBL3466341

SCHEMBL3466341

CCS(=O)(=O)c1cc([CH]C(N)=O)ccn1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34
CCR1 P32246 1/20 0.32
NFE2L2 Q16236 2/20 0.32
COMT P21964 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
CYP3A4 P08684 3/20 0.30
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
KIF11 P52732 1/20 0.30
PTGS1 P23219 1/20 0.30
PTGS2 P35354 1/20 0.30
NR3C1 P04150 2/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3126398 0.84 PIK3C3 (0.34) PIK3C3SCN10ANFE2L2POLBLMNA
SCHEMBL3465986 0.84 ALDH1A1 (0.33) PIK3C3SCN10ACCR1
SCHEMBL569043 0.82 CA2 (0.39) NFE2L2
SCHEMBL3465295 0.82 ALDH1A1 (0.32) PIK3C3SCN10ACCR1LMNA
SCHEMBL3465580 0.82 CA2 (0.34) SCN10ANFE2L2
SCHEMBL3129416 0.81 NFE2L2 (0.33) PIK3C3SCN10ACCR1NFE2L2
SCHEMBL27845940 0.80 NFE2L2 (0.34) SCN10ACCR1NFE2L2COMTCYP1A2
SCHEMBL3133420 0.78 KDM5C (0.41) PIK3C3SCN10ACYP1A2POLBCYP3A4
SCHEMBL3466299 0.78 NFE2L2 (0.33) SCN10ANFE2L2KDM4E
SCHEMBL3466883 0.78 HTR2A (0.36) PIK3C3POLBCYP3A4KDM4ENR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 EP disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCR4 PIK3C3 889/4885SCN10A 4175/4885CCR1 1/4885
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates CCR1, CCRL2, CCR4 PIK3C3 741/4885SCN10A 4709/4885CCR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.